Description
NVP-AEW541 is an inhibitor of IGF-1R that exhibits anticancer activity, inhibiting proliferation of pituitary tumor cells. This compound also increases sensitivity to other co-administered chemotherapeutics in pancreatic cancer cells, glioma cells, and prostate cancer cells.
References
Rubinfeld H, Kammer A, Cohen O, et al. IGF1 induces cell proliferation in human pituitary tumors - Functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors. Mol Cell Endocrinol. 2014 Apr 24;390(1-2):93-101. [Epub ahead of print]. PMID: 24769281.
Ioannou N, Seddon AM, Dalgleish A, et al. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer. 2013 Jan 31;13:41. PMID: 23367880.
Isebaert SF, Swinnen JV, McBride WH, et al. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):239-47. PMID: 21816290.
Premkumar DR, Jane EP, Pollack IF. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int J Oncol. 2010 Sep;37(3):633-43. PMID: 20664932.